Heart Disease Trial, Recruiting (NCT06282042)

Heart Disease Trial, Recruiting NCT06282042 Sponsor: Fundación para la Investigación Biosanitaria del Principado de Asturias Condition: Heart Disease

Printed from Voxsanity (voxsanity.com.au) — NCT06282042 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Heart Disease

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have moderate to severe or severe mitral regurgitation (a leaky heart valve) that is causing symptoms, which developed after a heart attack
People who are older than 18 years
People whose condition falls into a specific category (Type 2, 3, or 4) based on a published classification system for heart valve leakage after a heart attack — the trial site can confirm which category applies

Who may not be able to join:

People whose leaky heart valve is caused by a structural problem with the valve itself, such as a torn papillary muscle (a muscle that helps control the valve)
People whose heart pumping function is very low (below 25% on a specific heart strength test)
People who have been approved to have coronary artery bypass graft (CABG) surgery, which is a type of open-heart surgery to restore blood flow to the heart
People who are in cardiogenic shock, meaning their heart is unable to pump enough blood to meet the body's needs (also described as Type 1 in the classification system mentioned above)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 9 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Isaac Pascual, MD, PhD, Hospital Universitario Central de Asturias

Phone: 985101738

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06282042

Sponsor: Fundación para la Investigación Biosanitaria del Principado de Asturias

Phase: Not Applicable

Status: Recruiting

Condition: Heart Disease

Trial contact: 985101738

More information: https://clinicaltrials.gov/study/NCT06282042

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have moderate to severe or severe mitral regurgitation (a leaky heart valve) that is causing symptoms, which developed after a heart attack
People who are older than 18 years
People whose condition falls into a specific category (Type 2, 3, or 4) based on a published classification system for heart valve leakage after a heart attack — the trial site can confirm which category applies

Who may not be able to join:

People whose leaky heart valve is caused by a structural problem with the valve itself, such as a torn papillary muscle (a muscle that helps control the valve)
People whose heart pumping function is very low (below 25% on a specific heart strength test)
People who have been approved to have coronary artery bypass graft (CABG) surgery, which is a type of open-heart surgery to restore blood flow to the heart
People who are in cardiogenic shock, meaning their heart is unable to pump enough blood to meet the body's needs (also described as Type 1 in the classification system mentioned above)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 9 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Fundación para la Investigación Biosanitaria del Principado de Asturias

Registry

ClinicalTrials.gov

Start date

24 December 2024

Est. completion

16 June 2027

Where this trial is recruiting

🇮🇱 Israel 🇮🇹 Italy 🇳🇱 Netherlands 🇪🇸 Spain

Primary endpoints

All-cause death or Cumulative Heart Failure hospitalizations

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov